Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Interest in amphiphilic compounds and their role in pharmaceuticals keeps growing from decade to decade. 8-(2-Hydroxybenzamido) Sodium Octanoate emerged from the intersection of fatty acyl chain research and salicylamide structures. The roots of these developments stretch back to early studies in surfactant chemistry, linked to the desire for safer, more versatile excipients. Over time, scientific minds tinkered with various combinations, adding functional groups and sodium salts. These shifts paved the way for what later would become a valuable multi-domain molecule. Regulatory agencies such as the BP, EP, and USP have since shaped and standardized the handling and evaluation of this compound, moving it from synthetic novelty to a more mainstream ingredient in formulation labs. It now finds itself among the dozen or so excipients getting close attention due to its performance and safety profile, a position built on decades of scientific iteration and regulatory engagement.
8-(2-Hydroxybenzamido) Sodium Octanoate stands out as a synthetic compound integrating both fatty acid chains and an aromatic amide. Each batch sold as pharma grade always meets monographs from BP, EP, and USP. Its amphiphilic nature attracts researchers who constantly look for stable, functional compounds to enhance solvency, bioavailability, and compatibility with other common pharma ingredients. Production lots usually come in crystalline or powder form, carefully filtered and standardized. Color ranges from off-white to lightly beige, with only minimal odor, signs of a well-controlled synthesis. The label often highlights sodium content precisely, since any deviation could shift ionic balance or solubility. Its use thrives in labs that need both hydrophobic and hydrophilic interactions without sacrificing purity or ease of handling.
This compound has a molar mass centered between 325 and 340 g/mol, with sodium content usually confirmed by ICP-MS or AAS. Its melting point finds itself hovering near 155-165°C, resisting breakdown through standard shelf life windows. Density reads just above 1.2 g/cm³, offering stability on processing lines. Solubility in water marks a major draw; sodium ions boost dissolution, so it serves well in both aqueous solutions and buffered blends. Spectroscopically, a strong aromatic peak in hydrogen-NMR and an amide carbonyl stretch in FTIR show up clearly, aiding in quick batch verification. The structure resists aggressive hydrolysis at normal manufacturing pH ranges, vital for predictable behavior in finished tablets, suspensions, and even injectables. Shelf-stable for at least two years under refrigeration, this resilience attracts continuous demand in supply chains needing reliability.
Labeling requirements for BP, EP, and USP certifications expect a clear declaration of sodium content, batch number, production date, and specific grade. These grades define permissible limits for related impurities, including octanoic acid residuals and unreacted salicylamide, often measured down to below 0.1%. Microbial contamination controls remain strict; total aerobic microbial counts must fall under 10^2 cfu/g, and absence of pathogens like E. coli stands non-negotiable. Water content rarely exceeds 1.5%, usually measured by Karl Fischer titration. Labels often carry storage guidance, urging users to keep the compound cool and dry, shielded from ambient humidity. Pharmacopeial monographs cross-reference these figures, with manufacturers maintaining meticulous COAs and traceable data logs for each lot. Lot numbers, expiry dates, and tested parameter values all show up on each container to jump ahead of potential compliance bottlenecks.
Lab and industrial preparation centers on amidation, where 2-hydroxybenzoic acid derivatives react with octanoic acid chlorides under basic aqueous conditions. Sodium hydroxide neutralizes and catalyzes, driving amidation to completion. The reaction tank stays below 40°C to prevent side hydrolysis, with product precipitation monitored visually and by HPLC sampling. Crude material goes straight to filtration, followed by a series of ethanol washes to strip byproducts. Drying comes next—usually in circulating ovens kept under vacuum, which safeguards against oxidation. Each crystallization step monitored through FTIR and melting point analysis, ensuring each lot keeps within the specs seen in pharmacopeial standards. Final product passes through a classifier sieve before drum packaging and quality hold.
The amide and phenolic groups present unique opportunities for downstream chemical tweaks. Acylation of the aromatic ring gives way to custom derivatives for patent layering or process optimization. Sulfonation of the phenolic group brings up new solubility profiles, feeding pharmaceutical chemists looking to shape bioavailability. On a molecular level, the carboxylate group attached to sodium shows resilience to base hydrolysis but may break down under prolonged acidic treatment, something formulators monitor. Coupling reactions using carbodiimides have surfaced in process optimization, offering ways to connect the molecule with PEG chains or similar carriers. Each tweak unlocks fresh application routes, illustrating the broad chemistry landscape around one core structure.
Names in the literature stretch over 8-(2-hydroxybenzamido)octanoic acid sodium salt, sodium 8-(2-hydroxybenzamido)octanoate, and sometimes sodium capryloylsalicylamide. Pharmaceutical suppliers might call it by company-specific codes, but the pharmacopoeial names almost always win out in regulatory submissions. Other references include salicylamide caprylate sodium or simply “salicylamide octanoate sodium”, but careful review of the IUPAC or CAS naming ensures clarity for stakeholders across compliance, supply chains, and R&D settings.
Material safety data sheets for this compound put occupational safety up front. Its powdery form means users wear gloves and minimum FFP2-respirator masks to cut down on inhalation risk. Dermal exposure gets blocked with standard nitrile gloves. Fire safety ratings read low; flash point stays above 200°C, ruling out spontaneous ignition but keeping warehouse teams mindful of proper segregation away from oxidizers and acids. Chronic exposure studies show minimal bioaccumulation, but any handling mistake—especially inhalation—draws scrutiny under workplace safety audits. Regular training in GMP cleanrooms reinforces these precautions, while spills get managed with vacuum systems and containment pads. Documentation must be current, covering eye wash stations, spill clean-up steps, and chemical handling training logs to pass regulatory site checks.
Pharmaceutical folks look to this compound for its surfactant and stabilizing performance in solubilizing stubborn actives. In drug design, its pinpointed hydrophobic-hydrophilic balance helps solubilize poorly soluble drugs, stretching formulation possibilities for new tablets, liquids, and injectables. Hospitals deploy finished drugs containing it for pain management, anti-inflammatories, and sometimes extended-release pills. Secondary use cases exist in dermatology, where topical creams incorporate its amphiphilicity. Some biotech teams use it as a carrier in nanoparticle formulations, betting on its compatibility and safe metabolic breakdown. What ties them all together is the need for a reliable, well-characterized excipient or intermediate that stands up to tough regulatory scrutiny.
University and industry labs keep poking at both chemical and application edges of this molecule. Modification studies hunt for sites to graft polymers or sugars, hoping to improve targeting or extend half-life of active drugs delivered with its help. Analytical teams develop ever-sharper LC-MS and NMR-based methods to fingerprint impurities and spot degradation products. In the regulatory space, R&D investigators help fine-tune monographs, pushing for clearer impurity targets and robust validation workflows. Interest in modified-release dosage forms leads formulators to experiment with co-processed excipients, combining this compound with microcrystalline cellulose or HPMC to unlock better release profiles. Research summaries in annual pharma conferences reveal ongoing work in mechanistic toxicology, with modeling teams publishing new predictions about its metabolic fate in healthy and compromised livers.
Preclinical profiles skew toward low acute and chronic toxicity, giving developers confidence in its use. Oral LD50 in rodent studies lands well above typical exposure levels, and subchronic observations barely elicit changes in hepatic or renal parameters. Local tolerance fits into the comfortable range, especially when compared with older surfactants and carriers. In vitro cell culture studies using human hepatocytes have not flagged significant CYP induction or mitochondrial disruption. Genotoxicity panels return clean, negating carcinogenic worries for standard dosing. Of course, oversight bodies expect yearly renewal of this data, and researchers chase long-term pharmacokinetics—absorption, distribution, metabolism, and excretion curves—across diverse patient populations. Reports in toxicology journals keep the scientific community tuned into rare side effects, especially in high-dose or long-term use scenarios.
Development will likely go toward more biocompatible surfactants and drug carriers, but this compound's stable, well-studied profile means it will hold a place on excipient shelves for some time. Growth in precision medicine and custom drug delivery platforms could bring fresh demand, especially when tighter regulation closes off riskier alternatives. Emerging research areas hint that tweaks at the phenolic or amide sites could birth new intellectual property for delivery systems or diagnostic tools. Sustainability-minded teams scan for greener synthesis, aiming to curtail organic solvent use or switch to enzymatic pathways. Investment from both large and small molecule drug programs signals that the basic structure still answers unmet formulation needs. Ultimately, ongoing feedback between the bench and bedside will sculpt its next decade, but given its straightforward manufacturing and reassuring safety record, it seems set to remain a go-to choice in modern pharmaceutical toolkits.
Imagine working in a pharmacy lab. You battle stubborn powders and sticky compounds every day. Some drugs just don’t play nice with water. They clump up, they refuse to dissolve, and they drive everybody up the wall. That's the moment a molecule like 8-(2-Hydroxybenzamido) Sodium Octanoate steps in. This compound acts as a solubilizer—essentially a fixer for those impossible mixes. It wraps around the poorly soluble drug particles and pulls them into solution. For anyone who’s mixed aspirin into water and seen grit sink to the bottom, you’ll know why this is a big deal.
Countless life-saving drugs have a common problem—they don’t dissolve well, so the body can’t absorb them efficiently. Here’s where this compound earns real-world respect. By improving solubility, the medicine can actually reach a patient’s bloodstream faster and in greater amounts. There’s solid evidence in published studies: solubilizers like 8-(2-Hydroxybenzamido) Sodium Octanoate help get more of the active ingredient to where it matters most. A 2022 review from the Journal of Pharmaceutical Sciences points to a jump in available drug levels when these solubilizers are used.
Every parent knows the struggle of getting medicine into a child’s mouth when it tastes like chalk. This compound does more than dissolve drugs—in some situations, it helps mask flavors and cut that gritty texture. In pediatric and geriatric care, a smooth, palatable liquid can be the difference between a patient taking their medicine or refusing altogether. By breaking up particles and smoothing out tastes, this molecule makes life easier for pharmacists and patients alike.
A medicine should stay mixed, from the pharmacy shelf to the patient’s spoon. 8-(2-Hydroxybenzamido) Sodium Octanoate steps up here, too. As a dispersant, it keeps particles from settling out at the bottom. Think of shaking a cough syrup and not seeing a mudslide forming in the bottle. Pharmacies and hospitals depend on stable suspensions, and this ingredient helps prevent fluctuations in every dose poured or measured out.
Across developing countries, access to consistent, effective medicines can be a struggle. Poor storage conditions and variable raw materials make things harder. Solubilizers like 8-(2-Hydroxybenzamido) Sodium Octanoate guard against medicine separating or losing punch during transport. That reliability means more patients get the right treatment, especially where refrigeration isn’t always an option.
No ingredient is free from questions. Some people wonder about possible side effects or interactions with other drugs. Regulatory agencies like the FDA and EMA set strict guidelines for safety. More research and post-market monitoring can spot rare issues early. Drug makers can work with pharmacists to keep improving safety profiles, maybe by testing lower dose options or combining with other helper molecules. Training pharmacy staff on proper mixing and storage makes a huge difference in everyday safety, too.
If there’s one thing pharmacy and healthcare workers value, it’s reliability. Better ingredient sourcing, real-world testing, and clear communication between manufacturers and end-users keep the medicines trustworthy. As more new drugs come on the market, the demand for smart solubilizers like 8-(2-Hydroxybenzamido) Sodium Octanoate will only grow. Keeping the focus on safety, science, and practicality serves both the professionals and the patients who count on them.
Every time a chemist talks about 8-(2-Hydroxybenzamido) Sodium Octanoate, questions immediately surface on purity and what it takes for this compound to land on a pharmacist’s shelf. Pharmaceutical production moves on precision and tight controls. Getting this right for a niche compound like this one, which serves a role as a potential excipient, means holding up three major playbooks: the British Pharmacopoeia (BP), the European Pharmacopoeia (EP), and the United States Pharmacopeia (USP).
Pharma grade standards in BP, EP, and USP don’t leave much room for guessing. These compendia set thresholds that carry legal teeth. I learned early on that manufacturers look at identification, purity, heavy metals, and microbial limits, and they don’t compromise.
Identification matters for traceability and safety. Labs use IR spectroscopy and HPLC as baseline checks. Every genuine batch comes with certificates showing sharp peaks at the right wavelengths, which guards against slip-ups from the raw material supplier or mistakes during synthesis.
Purity stands as the stark line between pharma and technical grade. Each pharmacopoeia anchors purity at 98.0% minimum. From my side, the challenge always comes from removal of closely related impurities. Manufacturing experience tells me that even small process drifts can throw a batch off-spec. I’ve seen how column chromatography tweaks or an extra washing step shift purity from 96% to 99%. Those changes mean the difference between “for research use only” and a pharma release certificate.
Impurities can’t hide under the radar. The EP and BP both cap single identified impurities at 0.5% and total related substances at 1.0%. Unknowns get flagged quickly if they nudge past the 0.1% mark. For the USP, requirements usually align, sometimes going even tighter depending on excipient use or route of administration. Detailed HPLC runs help stamp out those hidden peaks—every peak mapped, assigned, and documented.
Heavy Metals testing in all three standards requires that lead, mercury, arsenic, cadmium, and others stay below designated ppm levels—think 10 ppm or less, occasionally much lower. It takes precise atomic absorption or ICP-MS setups.
Water Content and Loss on Drying make a surprising difference in physico-chemical behavior. Limits typically hover below 2.0% for these grades, double-checked by Karl Fischer titration or gravimetric drying. Formulators know too well that exceeding these can mess with stability and shelf life.
Microbial limits close the loop, with strict criteria for total viable aerobic count, absence of pathogens like E. coli or Salmonella, and yeast/mold thresholds. For injectable or parenteral medicines, endotoxin levels drop even further—right down to 0.25 EU/mg.
Pharmacopoeial grades require more than passing a few tests. Good Manufacturing Practice (GMP) documents need to back every step, with validated methods, batch traceability, and retention samples. Lab notebooks stack up with trend data to spot creeping changes before they reach scale. Auditors want to see not just numbers but the story of each batch—from raw input to final product release.
Cost always comes up in meetings. Chasing pharmaceutical grade specs costs more, from solvent purity to analytical checks. That premium pays off in confidence and regulatory leeway, especially during product recalls or market expansion. My experience says skimping leads to longer term headaches—reprocessing, recalls, and lost trust.
Supply chain transparency makes a big difference. Years ago, an out-of-spec lot slipped past a different supplier’s loose controls, hitting a production halt. Now, more firms demand site audits and routine third-party impurity testing before award contracts.
Pharma grade 8-(2-Hydroxybenzamido) Sodium Octanoate could tighten its standards further, mirroring the trend in other excipients. Real progress could mean pushing trace metal detection thresholds lower with new analytical technology. That step makes sense as health authorities raise the bar year after year for patient safety.
Handling any chemical demands respect for its risks and properties, and 8-(2-Hydroxybenzamido) sodium octanoate is no different. It’s not always lurking in household cleaners, but plenty of research labs and industry settings deal with it regularly. Storing and handling it well protects your team, your work, and even your funding if you want to keep those avoidable incidents off the books. Years spent in cramped university stockrooms taught me that some protocols might look excessive on paper, but accidents rarely cut you a warning.
This compound responds poorly to heat, light, and moisture. Put simply, you don’t toss it in a random supply drawer or “out of the way" corner. A climate-controlled chemical cabinet works best. Look for dry, cool spaces—think 15°C to 25°C—away from steam lines, heating vents, or windows that pull in sunlight. Moisture triggers clumping or even potential chemical breakdown. I once saw a bottle ruined from sitting a single weekend next to a faulty A/C unit. The powder inside caked, and lab personnel grumbled as pounds of material had to be replaced.
Every label matters more than you think. Mark containers clearly with the contents, date received, and any hazard designations. If a new intern can’t walk up and immediately get the details from your labeling system, it’s time to re-think your approach. The best labs I’ve worked with painted lines on shelving, assigned shelf spots strictly by chemical family, and kept nothing unidentified in shared fridges.
Spills don’t care about your deadlines. An emergency kit should stay within arm’s reach of any workspot handling this compound. Gloves made from nitrile or neoprene, fitted goggles, and a simple dust mask protect against accidental splashes or airborne powder. Having a small bench brush or dedicated vacuum beats using paper towels, which might react with spilled material if you aren’t careful. Sodium octanoate’s salt form isn’t especially vicious, but respiratory irritation or skin contact hurts productivity—and, frankly, morale. After seeing a coworker develop a rash because he skipped sleeves and a fresh pair of gloves, I never cut corners on protection.
All leftover material and even aspirated dust deserve respect. Secure chemical waste in leak-proof, labeled containers. You don’t want confusion between waste and stock—nobody benefits from that mix-up during a busy shift. Track all inventory, usage, and disposal with written records. I once watched a new technician dump waste into the wrong drum—correcting that mistake killed the rest of our afternoon and almost led to a costly fine.
Fume hoods and bench shields keep stray dust and vapors from reaching faces and hands. Installing even a basic air filter above your workspace reduces risk. You’ll notice better air quality and avoid those nagging sore throats that creep up during peak research periods. In spaces without dedicated ventilation, keeping work under a local extractor offers extra insurance.
Safety walks and refreshers work wonders. I’ve seen well-designed protocols turn clumsy hands into careful ones. Every worker benefits from a brief review of the compound’s data sheet and a hands-on demonstration of correct technique. Practicing what to do during a spill or a fire drill means fewer stumbles when real problems hit.
Safe management of 8-(2-Hydroxybenzamido) sodium octanoate relies on treating every step—storage, handling, cleanup—with consistency and care. You make your workspace easier and safer for the next person. That’s the kind of stewardship that sets truly professional labs and workspaces apart.
Mixing active pharmaceutical ingredients with excipients should be smooth, but the real world often throws in surprises. 8-(2-Hydroxybenzamido) Sodium Octanoate isn't a household name, but in drug development, even obscure compounds can shake up the routine. Walking into a formulation lab, you’ll find benches lined with bottles of microcrystalline cellulose, lactose, magnesium stearate, and polyethylene glycol. These aren’t just placeholders—they set the stage for how a drug performs.
This compound is unique, combining a sodium salt with an aromatic group. The phenol group may throw some curveballs with certain excipients, especially those prone to acid-base reactions or oxidative degradation. For example, magnesium stearate commonly acts as a lubricant in tablet blends. If there’s any hint of residual acidic or basic impurities in the drug or the excipient, small reactions start to pop up, pulling down shelf life and raising red flags in stability studies.
Published pre-formulation studies give a clue: phenol-containing agents sometimes form weak hydrogen bonds with cellulose or lactose, possibly impacting flow properties or even dissolution rates. I remember testing a similar aromatic drug—exposed to lactose, it didn’t just blend, it clumped oddly under high humidity. That’s real-life evidence that theoretical compatibility doesn't always match how powders act in a granulator.
A pharmacy rarely escapes moisture. Some excipients, like starch and hydroxypropyl methylcellulose (HPMC), soak it up like a sponge. If water seeps in, the sodium octanoate group could hydrolyze over time or even interact with polar parts of an excipient, sparking off unwanted product—even at room temperature. Add the heat from a standard granulation line, and surprises mount up.
Shifting from chemical to physical world, this compound may jam up modern tablet presses. An eight-carbon chain makes the molecule oilier than a basic sodium benzoate, so it doesn’t always glide over tableting punches. I struggled with a related compound that just didn’t run right on a high-speed press, needing extra glidant and anti-caking agents compared to the same setup with paracetamol. Polyethylene glycol or silicon dioxide helps, but each change nudges testing, process tweaks, and eventually patient acceptability.
Solid science steps in to tackle these obstacles. Differential Scanning Calorimetry (DSC) and Fourier Transform Infrared Spectroscopy (FTIR) help spot incompatibilities before scale-up. Forced degradation studies under stress conditions even pick up on subtle incompatibilities invisible in early screens. Suppose things still go sideways with sticking or clumping—coatings or alternative excipients rescue many launches, though they come with cost and regulatory twists. Screening excipients before committing becomes the best defense. Rather than squeezing a new molecule into old frameworks, each system calls for customization based on real interactions discovered in early trials.
A tablet isn’t just a chemistry set—it ends up in someone’s routine, sometimes every morning. Unexpected incompatibility doesn’t stay in the lab, either. Anything that affects shelf life, taste, or even physical appearance can erode trust, triggering queries from regulators and users alike. Open communication, honest reporting of results, and a history of safe choices build patient and clinician confidence in new compounds, even obscure ones like 8-(2-Hydroxybenzamido) Sodium Octanoate.
Every year, pharmaceutical companies and labs buy thousands of ingredients and chemicals to support their work. With so many parties touching the same product, questions about safety, quality, and compliance naturally follow. Documentation fills in those gaps. Each certificate and sheet tells a piece of the story, helping buyers and end users understand exactly what has been produced, how it’s handled, and where it comes from.
A Certificate of Analysis (COA) is not just a slip of paper. It shows the actual results from specific testing, run on a specific batch. Instead of relying on hopes and promises, a COA lets buyers compare what was ordered with what arrived. Labs looking for consistency know the numbers on that COA allow them to trust that the next order will work like the last one. In my own work, I have caught more than one issue—the color, smell, or even assay values don’t always match up. Without a COA, you run blind.
Moving chemicals around isn’t just about paperwork; it’s about safety. A Material Safety Data Sheet (MSDS) provides information needed for storage, handling, and what to do if something goes wrong. In one real situation in a small lab, a misplaced container leaked overnight. Because the MSDS was part of the documentation, staff quickly identified proper clean-up procedures and medical steps if exposure occurred. These sheets are not just formalities—they have real consequences for anyone working up close with these materials.
Good Manufacturing Practice (GMP) certification signals a company’s commitment to consistent production and quality. Anyone who has worked in manufacturing knows shortcuts can creep in. GMP brings structure and accountability. Suppliers with sound GMP records tend to have fewer recalls and slip-ups, which saves time, money, and reputation. Regulatory bodies require this for a reason: it means there’s a working system behind the promises.
Transmissible Spongiform Encephalopathies (TSE) and Bovine Spongiform Encephalopathy (BSE) made headlines years ago. The world learned how animal-derived materials sometimes bring big risks. TSE/BSE-free certificates show a company is sourcing raw materials with traceability and transparency. My colleagues in biotech won’t use animal content at all unless these assurances appear, which keeps prions and other hard-to-detect risks out of the conversation.
Mistakes with documentation and missing certificates led to delayed launches and even recalls. I’ve seen teams order top-dollar chemicals and still have project delays because a needed COA or MSDS didn’t arrive. Not having clear provenance or risk assessments creates headaches—not only for labs or manufacturers, but also for the regulatory teams that step in after accidents.
Suppliers, buyers, regulators, and frontline staff all benefit from a clear, shared record of what’s being bought and used. More companies now ask for digital and tamper-proof records, not just paper. Building in these processes from the beginning simplifies audits and prevents last-minute scrambles. Whether working in pharma, food, or industry, people want certainty. Taking documentation seriously paves the way for safer workplaces, smoother research, stronger audits, and ultimately better public health outcomes.
Chengguan District, Lanzhou, Gansu, China
